spacer
home > epc > autumn 2008 > electric avenue
PUBLICATIONS
European Pharmaceutical Contractor

Electric Avenue

THE BENEFITS OF ELECTRONIC DATA CAPTURE

The promise of information technology is being realised by businesses around the world. This is evidenced is in the way computing power allows tasks, and even entire processes, to be completed whilst providing the additional benefits of improved methodologies, higher speeds and lower costs. Now, stakeholders of electronic data capture (EDC) are looking to achieve similar benefits in their clinical trial processes earlier on, prior to deploying a finished solution. Some believe the answer lies in a more effective way of implementing EDC. They contend that the days of expensive technology transfer, long implementation times and resource-intensive processes are coming to an end.

As the pharmaceutical industry moves higher up the learning and experience curves for EDC, there is less debate about the need for, and benefits of, EDC solutions as a powerful and necessary component in the clinical trial landscape. The discussion has moved beyond the question of whether EDC is useful, because these web-based systems are allowing investigators to log their findings directly into a centralised database, delivering accurate data in near real-time. These data may then be analysed for such purposes as reviewing the progress of clinical trials, supporting trial adaptation and reducing the costs of providing statisticians with study information. EDC also helps improve efficiencies – a benefit of great interest in drug development.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simon Hawken has more than 20 years’ experience of selling solutions into the biopharmaceutical sector. He currently serves as Director of Business Development for eResearchTechnology, Inc – the well-established cardiac safety leader also providing eClinical solutions – and is based in the UK. He holds a BA degree in Economics and has worked for IMS Health, IBM Corporation, Xerox and BEA Systems Inc, among others.
spacer
Simon Hawken
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement